Oncorus, Inc.
DelistedCIK 1671818fmd_11GA3AJDQX88DW2CRZJR1AGMZNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2023, 16 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Realized investment gains (losses) | – | – | 0 | 0 |
| Research and development | 24 | 27 | 45 | 55 |
| Total operating expenses | 31 | 37 | 65 | 77 |
| Operating income | (31) | (37) | (65) | (77) |
| Interest and investment income | 1 | 0 | 0 | – |
| Other non-operating income (expense) | 0 | (11) | 0 | (1) |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | (31) | (48) | (65) | (77) |
| Net income to common shareholders | (35) | (57) | (65) | (77) |